Today, the CEO of Emergent Biosolutions (NYSE: EBS), Daniel Abdun-Nabi, bought shares of EBS for $395.2K.
Following this transaction Daniel Abdun-Nabi’s holding in the company was increased by 17.67% to a total of $10.93 million. Following Daniel Abdun-Nabi’s last EBS Buy transaction on June 07, 2018, the stock climbed by 12.1%.
See today’s analyst top recommended stocks >>
Based on Emergent Biosolutions’ latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $220 million and quarterly net profit of $50.14 million. In comparison, last year the company earned revenue of $101 million and had a net profit of $4.62 million. EBS’s market cap is $3.25B and the company has a P/E ratio of 29.10. Currently, Emergent Biosolutions has an average volume of 459.3K.
Based on 4 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $63.00, reflecting a -3.6% downside.
Daniel Abdun-Nabi’s trades have generated a 19.0% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures that address public health and national security threats. It includes Chemical, Biological, Radiological, Nuclear and Explosive or CBRNE threats; as well as emerging infectious diseases.
